An unproven and unapproved procedure has harmed some patients.
The agency's oncology staff will work closely with physicians seeking treatments through the FDA's "expanded access" program.
The studies build on past research showing that the law, under legal and political attack by the Trump administration, has improved access to health care, in part by expanding Medicaid.
The opinion sides with Texas, which the agency blocked from importing an overseas drug needed in executions.
The device is already sold in dozens of other countries with varying success, but it has triggered debate among U.S. health experts over whether IQOS would help or hurt overall public health.
If approved, the increased reimbursements for CAR T-cell therapy and “breakthrough” devices would go into effect on Oct. 1.
The agency ordered the two remaining manufacturers of surgical mesh used for certain pelvic operations to stop selling the products immediately, citing the lack of a “reasonable assurance” of safety and effectiveness.
New advice to industry will aim to provide clarity on nonaddictive alternatives, FDA Commissioner Scott Gottlieb says.